In summary, in this study, a four-gene set (UBE2L6, BATF2, SERPING1, and VAMP5) was validated as a novel method for the diagnosis of active PTB, as well as a biomarker for monitoring anti-TB treatment efficacy. The gene discussed is BATF2; the disease is tuberculosis.